TTK Healthcare — 360° view

TTK Healthcare, a company in the Diversified industry, reported revenue of ₹233 crore and net profit of ₹223 crore for the September 2026 quarter.

TTK Healthcare (NSE: TTKHLTCARE) closed at ₹1,110.15 on 20 Nov 2026, down 0.0% over the past year. Its market capitalisation is ₹1,569 crore and it trades at 21.6 times earnings.

Share price
₹1,110.15 (20 Nov 2026)
Market cap
₹1,569 Cr (20 Nov 2026)
P/E
21.60 (20 Nov 2026)
Revenue
₹233 Cr (September 2026 quarter)
Net profit
₹223 Cr (September 2026 quarter)
ROCE
8.04% (FY26)
ROE
6.30% (FY26)
Book value
₹953 (FY26)
Dividend yield
0.90% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,247.00 / ₹735.00 (20 Nov 2026)
1-year return
-0.0% (to 20 Nov 2026)
Sector
Diversified
Industry
Diversified
Symbol
NSE: TTKHLTCARE

TTK Healthcare Ltd is a standalone TTK Group company in consumer /OTC brands, animal health, medical devices, condoms/sexual-wellness and ready-to-fry foods. Human Pharma was divested in May 2022; agreements to sell EVA and Good Home were signed in July 2026.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.